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ABSTRACT
Background
In the absence of an effective vaccine, HIV continues to spread globally, emphasizing the
need for novel strategies to limit its transmission. Pre-exposure prophylaxis (PrEP) with
antiretroviral drugs could prove to be an effective intervention strategy if highly efficacious and
cost-effective PrEP modalities are identified. We evaluated daily and intermittent PrEP regimens
of increasing antiviral activity in a macaque model that closely resembles human transmission.
Methods and Findings
We used a repeat-exposure macaque model with 14 weekly rectal virus challenges. Three
drug treatments were given once daily, each to a different group of six rhesus macaques.
Group 1 was treated subcutaneously with a human-equivalent dose of emtricitabine (FTC),
group 2 received orally the human-equivalent dosing of both FTC and tenofovir-disoproxil
fumarate (TDF), and group 3 received subcutaneously a similar dosing of FTC and a higher dose
of tenofovir. A fourth group of six rhesus macaques (group 4) received intermittently a PrEP
regimen similar to group 3 only 2 h before and 24 h after each weekly virus challenge. Results
were compared to 18 control macaques that did not receive any drug treatment. The risk of
infection in macaques treated in groups 1 and 2 was 3.8- and 7.8-fold lower than in untreated
macaques (p ¼ 0.02 and p ¼ 0.008, respectively). All six macaques in group 3 were protected.
Breakthrough infections had blunted acute viremias; drug resistance was seen in two of six
animals. All six animals in group 4 that received intermittent PrEP were protected.
Conclusions
This model suggests that single drugs for daily PrEP can be protective but a combination of
antiretroviral drugs may be required to increase the level of protection. Short but potent
intermittent PrEP can provide protection comparable to that of daily PrEP in this SHIV/macaque
model. These findings support PrEP trials for HIV prevention in humans and identify promising
PrEP modalities.
The Editors’ Summary of this article follows the references.
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With an estimated 33.2 million people worldwide living
with HIV at the end of 2007 and an estimated 2.5 million new
infections in 2007 acquired mostly through sex, HIV/AIDS
continues to be a major global health challenge [1]. Currently,
no vaccine is available to prevent HIV, and it is unlikely that
one will be developed soon. Pre-exposure prophylaxis (PrEP)
with antiretroviral drugs is gaining considerable attention as
a possible biomedical intervention strategy to prevent sexual
transmission of HIV [2–5]. PrEP is a proven concept for other
infectious diseases like malaria. Mathematical models esti-
mate that over the next 10 y, an effective PrEP program could
prevent 2.7 to 3.2 million new HIV-1 infections in sub-
Saharan Africa [6]. This potentially signiﬁcant public health
beneﬁt requires a very high PrEP efﬁcacy and might be lost or
substantially reduced with a PrEP efﬁcacy of ,50%. There-
fore, identifying highly effective PrEP modalities is critical. In
sexual transmission, HIV ﬁrst replicates at a low level at the
mucosal point of entry in the new host [7,8]. Effective PrEP
can exploit this brief period of virus vulnerability by blocking
HIV from establishing itself as a persistent infection.
Simian immunodeﬁciency virus (SIV) infection of maca-
ques is a well-established model for HIV transmission that
can provide data about the relative efﬁcacy of different PrEP
strategies, thereby informing the development of PrEP trials
in humans. The use in PrEP of drugs that are approved for
the treatment of HIV-1-infected persons is advantageous
because of the known antiviral activity, safety, and drug
resistance proﬁles of these drugs. Previous work in macaque
models has largely focused on single-drug PrEP with
tenofovir, a nucleotide reverse transcriptase (RT) inhibitor,
and has shown the prophylactic efﬁcacy of this drug against
SIV transmission [9–11]. More recent work with tenofovir
disoproxil fumarate (TDF), the currently approved oral
prodrug, showed that daily PrEP with TDF at dosing
comparable to the human dose was only partially protective
against rectal or oral SIV/SHIV transmission [12,13]. In a
recently reported Phase II clinical trial with TDF, two PrEP
failures were reported compared to six infections in the
placebo group [14]. The efﬁcacy of TDF could not be
conclusively evaluated because of the small number of HIV
infections observed during the trial.
In this study, we evaluated PrEP efﬁcacy of regimens
containing the nucleoside RT inhibitor emtricitabine (FTC)
alone or in combination with either tenofovir (in subcuta-
neous regimens) or TDF (in oral regimens). FTC is well
tolerated and very potent, and has synergistic to additive
effects with tenofovir. Both drugs have long intracellular half-
lives and are co-formulated in a once-daily pill (Truvada) [15–
18]. PrEP efﬁcacy was measured in a repeat-low-dose
exposure model in macaques that is highly relevant to PrEP
in humans in three major ways. First, the SHIV virus
challenge contains an R5 tropic HIV-1 envelope that
resembles naturally transmitted viruses. Second, the mucosal
transmission component uses a lower and more physiologic
virus inoculum than what is conventionally used in the single
high-dose challenge models [19,20]. Third, while single-dose
models measure protection against one transmission event
per animal, this model evaluates protection against multiple
transmission events in each animal resulting from repeated
virus exposures. In this model, protection by PrEP is
measured by the degree that infection is prevented or by
the increase in the number of exposures needed to infect
macaques.
Methods
Animals and Interventions
The Animal Care and Use Committee (AICUC) of the
Centers for Disease Control and Prevention (CDC) approved
this study (protocol CDC-AICUC 1414OTTMONC-A5). All
animal procedures were done at the animal facilities at CDC.
Results reported and analyzed adhere to the predetermined
study design and objectives.
The study design is shown in Figure 1. Three drug
treatments with different antiviral activity were each given
once daily to a group of six rhesus macaques. Group 1 was
treated subcutaneously with a human equivalent dose of FTC
(20 mg/kg; see next paragraph). Group 2 received oral FTC
and TDF (20 mg/kg and 22 mg/kg, respectively) at a dose
equivalent to Truvada in humans. Group 3 received subcuta-
neous FTC (20 mg/kg) and a higher dose of tenofovir (22 mg/
kg). Based on approximately double the molecular weight and
a 25%–50% tenofovir bioavailability in macaques following
oral TDF administration, this dose corresponds to about 66–
88 mg/kg of TDF given orally, or 3- to 4-fold the human-
equivalent dosing. Intermittent PrEP was given to a fourth
group of macaques (group 4) who received subcutaneously
the FTC and high-dose tenofovir used in group 3 only 2 h
before and 24 h after each weekly virus challenge. A total of
18 control macaques did not receive any drug treatment. Of
these macaques, nine were part of this study and nine were
historical controls from earlier studies done under identical
conditions in Rhesus macaques with the same virus stock,
inoculum size, and inoculation protocol.
Oral administration of FTC and TDF was performed by
mixing the drug powders with fruit (apples or bananas and
infrequently oranges). Stability analysis for up to 24 h by high-
pressure liquid chromatography (HPLC) demonstrated that
TDF was stable in fresh apple, banana, or orange juice (96% in
fruit compared to 98% in water; unpublished data). Macaques
were observed to ensure they had taken the drugs. Overall
daily drug ingestion was very high; animals missed only one to
seven doses during the whole study period. Infected animal
AG-81 (see below) missed ﬁve doses; one dose 14 d before and
four sporadic doses after viral RNA was detected in plasma.
Infected animal AI-54 only missed one dose 10 d before the
ﬁrst detectable RNA. Stock solutions of tenofovir and FTC
were prepared in distilled water or phosphate-buffered saline,
respectively, and injected subcutaneously [21,22].
Tenofovir disoproxil fumarate (9-[(R)-2[[bis[[isopropoxy-
carbonyl)oxy]-methoxy] phosphinyl]methoxy]propyl]adenine
fumarate; TDF), tenofovir ((R)-9-(2-phosphonylmethoxyprop-
yl) adenine; PMPA), and emtricitabine (5-ﬂuoro-1-(2R,5S)-[2-
(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; FTC) were
kindly provided by Gilead Sciences through a material
transfer agreement.
Macaque Model of Rectal SHIV Transmission
The efﬁcacy of different PrEP modalities was evaluated
using a repeated exposure macaque model of rectal trans-
mission [12,19]. Rhesus macaques were exposed rectally once
weekly for up to 14 wk to a SHIVSF162P3 chimeric virus that
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a background of SIVmac239 (National Institutes of Health
[NIH] AIDS Research and Reference Reagent Program
[23,24]). The SHIV162p3 challenge dose was 10 TCID50 or
7.6310
5 RNA copies, which is within the range of HIV-1 RNA
levels in semen (10
3–10
6 copies/ml) during acute infection in
humans and higher than the levels (10
2–10
4 copies/ml) seen
after primary viremia [20,25]. Virus exposures were done 2 h
after drug treatment by a non-traumatic inoculation of 1 ml
of SHIVSF162P3 into the rectal vault via a sterile gastric feeding
tube of adjusted length [19]. Macaques were anesthetized
using standard doses of ketamine hydrochloride. Anesthe-
tized macaques remained recumbent for at least 15 min after
each intrarectal inoculation. Virus exposures were stopped
when a macaque became SHIV RNA positive. All experiments
were done under highly controlled conditions by the same
personnel using the same virus stock, inoculum dose, and
inoculation method.
The four study groups were staggered for logistic feasibility
given the long follow-up (6.5 mo) in this model and to avoid
unnecessary use of macaques. Group 3, which received the
highest dose of FTC/tenofovir, was started before the FTC-
only animals in group 1 because if this combination was not
protective, testing FTC only would have not been pursued.
Similarly, the intermittent FTC/tenofovir arm was done after
data were available from the daily interventions. Four
protected animals (three from group 3, one from group 1)
were used again after a washout period of 8–12 mo; two were
used in group 2 and two were used in group 4. Details on all
the individual macaques, the regimens received, the sequence
and outcome of each series, and the re-use of four animals are
shown in Text S1 and Table S1. Blinding of the animal
handlers was not done.
Drug Doses
Small mammals usually eliminate drugs faster than larger
mammals [26,27]. We therefore performed single-dose phar-
macokinetic studies in Rhesus macaques to determine the
FTC and TDF doses that achieve plasma and intracellular
levels comparable to those seen clinically in humans. Six
macaques were each given 48, 30, 20, 16, 15, and 12 mg/kg FTC
by oral gavage; plasma and intracellular drug levels in
Figure 1. Study Design and Interventions
(A) Daily PrEP. Macaques were drug-treated 7–9 d before the first virus inoculation. Treated animals that remained negative during the 14 challenges
received drug for an additional 28 d. Treated animals that became infected continued treatment to monitor plasma viremia and drug resistance
emergence.
(B) Intermittent PrEP. Macaques received FTC and tenofovir only 2 h before and 24 h after each weekly rectal challenge.
(C) Untreated control macaques.
Infection of macaques was monitored weekly by PCR and serologic testing. The treatment groups were staggered; four of 33 macaques were used in
two separate arms (see Methods, Text S1, and Table S1).
doi:10.1371/journal.pmed.0050028.g001
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mined as described below at 1, 2, 4, 8, and 24 h. The area
under the plasma concentration time curve (AUC) values over
a 24 h interval increased linearly with the FTC dosing
(unpublished data). The dose of 20 mg/kg FTC resulted in an
AUC value comparable to that achieved in humans receiving
200 mg FTC (13.2 lg 3 h/ml and 10 6 3.1 lg 3 h/ml,
respectively) [17]. Intracellular FTC-triphosphate (FTC-TP)
levels in this animal were essentially similar to those in
humans [17]. FTC-TP levels were highest at 1 h (1,419 fmol/10
6
cells), between 1,173–966 fmol/10
6 cells from 2–8 h, and 273
fmol/10
6 cells at 24 h. To assess oral bioavailability of FTC in
macaques, two additional macaques received a dose of 11 or
17 mg/kg of FTC subcutaneously. Plasma FTC levels (AUC
values of 6.1 and 12.2 lg3h/ml, respectively) were comparable
to those achieved in the two macaques that received 12 or 16
mg/kg of FTC orally (7.9 and 11.2 lg 3 h/ml, respectively)
indicating approximately 100% absorption. Therefore, we
considered a once-daily oral or subcutaneous dose of 20 mg/kg
of FTC as comparable to the dosing currently used in humans.
In humans, a wide range of tenofovir exposure is generally
seen with once daily dosing of 300 mg of TDF (plasma AUC
values of 2.3 6 0.69 lg 3 h/ml; range, 2.1–3.2 lg 3 h/ml) [28].
We performed single-dose pharmacokinetic studies in ﬁve
macaques that were each given by oral gavage a dose of 15, 20,
24, 37, and 46 mg/kg. Consistent with previous studies, we
found a linear relationship between the dose of TDF and
plasma AUC values. We also found that a dose of 20 or 24 mg/
kg of TDF resulted in plasma tenofovir levels (AUC values of
3.2 and 3.4, respectively) that are within the range of those
achieved in humans, while the other doses were outside this
range (1.3, 4.1, and 5.8 lg 3 h/ml for 15, 37, and 46 mg/kg,
respectively) [12,13,27,28]. Mean intracellular tenofovir-di-
phosphate (tenofovir-DP) levels measured between 1–4 h in
these two macaques were 107 fmol/10
6 cells (range, 60–169
fmol/10
6 cells) and 248 fmol/10
6 cells (range, 175–335 fmol/10
6
cells), respectively, also comparable to the levels observed in
humans 1–4 h after oral administration of 300 mg TDF (129–
373 fmol/10
6 cells) [16]. We therefore considered a once-daily
dose of 22 mg/kg of TDF to be equivalent to the human dose.
SHIV RNA Virus Load Assay and Amplification of Proviral
Sequences
Plasma SHIV RNA was quantiﬁed using a real-time RT-PCR
assay previously described [12]. This assay format has a
sensitivity of 50 RNA copies/ml. RNA was extracted from
virus pellets obtained by ultracentrifugation of 1 ml plasma.
Prior to RNA extraction and to control for the efﬁciency of
extraction, a known amount of virus particles (3 3 10
5) from
an HIV-1 CM240 virus stock was added to each plasma
sample. Reverse transcription and PCR ampliﬁcation of SHIV
(gag) and HIV-1 (env) sequences was done using primers
speciﬁc for SIVmac239 and HIV-1 CM240, respectively [12].
HIV-1 CM240 was obtained from the NIH AIDS Research and
Reference Reagent Program. Ampliﬁcation of proviral DNA
from PBMCs was done as previously described using primers
and probes speciﬁc for SIVmac239 pol [19].
Detection of Genotypic Resistance by Standard and
Sensitive Assays
FTC and tenofovir resistance was monitored by standard
sequence analysis of SIV RT (551 bp; amino acids 52 to 234)
and by sensitive allele-speciﬁc real-time PCR methods for the
K65R and M184V mutations. Sequence analysis was done
from plasma viruses using an RT-PCR procedure as pre-
viously described [12]. The Vector NTI program (version 7,
2001) was used to analyze the data and to determine deduced
amino-acid sequences. Detection of low-frequency K65R and
M184V mutants in plasma by real-time PCR was done as
previously described [29]. A similar testing approach is used
to assess minority drug-resistant HIV subpopulations in
humans [30]. The sensitive SIV assays can detect 0.4% of
K65R and 0.6% of M184V cloned sequences in a background
of wild-type plasmid.
Serology
Virus-speciﬁc serologic responses (IgG and IgM) were
measured using a synthetic-peptide EIA (Genetic Systems
HIV-1/HIV-2; BioRad) assay.
Drug Levels in Plasma and in Peripheral Blood
Mononuclear Cells
Tenofovir and FTC were extracted from 100 ll plasma by
protein precipitation with 400 ll methanol containing 250
nM 3TC as an internal standard. Following precipitation, the
solution was maintained at 4 8C for 10 min followed by
vortexing for another 10 min. The supernatant was then
evaporated to dryness in a heated vacuum centrifuge. Dry
samples were stored at  20 8C until liquid chromatography–
tandem mass spectrometry (LC-MS/MS) analysis. Drug levels
were analyzed by using HPLC (LC Packings Ultimate 3000
modular LC System; Dionex) and ultra triple quadrupole
mass spectrometer (Thermo Electron). Calibration curves
were generated from standards of tenofovir and FTC by serial
dilutions in human plasma over the range from 3.33 to
100,000 ng/ml. The lower limit of quantiﬁcation was 3.33 ng/
ml. All calibration curves had r
2 values greater than 0.99.
Tenofovir-DP and FTC-TP were extracted from macaque
PBMCs using 60% methanol. Brieﬂy, PBMCs were washed
twice with phosphate-buffered saline and then resuspended
in 1 ml of ice-cold methanol containing 4 nM 3TC-TP as an
internal standard for both tenofovir-DP and FTC-TP.
Samples were extracted overnight at  80 8C, centrifuged,
and dried under a stream of air. Dried extracts were
maintained at  80 8C until analysis. Prior to analysis, each
sample was reconstituted in 100 ll 50 mM ammonium acetate
buffer (pH 7.0) and centrifuged at 17,000g to remove
insoluble particulates. Calibration curves were generated
from standards of tenofovir-DP and FTC-TP by serial
dilutions in blank human PBM extract (10
7 cells/100 ll5 0
mM ammonium acetate buffer) over the range from 0.25 to
10 nM for tenofovir-DP and 2.5 to 100 nM for FTC-TP. The
lower limit of quantiﬁcation was 0.25 nM for tenofovir-DP
and 2.5 nM for FTC-TP. All calibration curves had r
2 values
greater than 0.99. Drug levels were analyzed by HPLC (Agilent
1100 LC system; Agilent Technologies) with mass spectrom-
etry detection (TSQ Quantum; Thermo Electron).
Statistical Methods
The exact log-rank test was used to ascertain statistical
difference between groups of macaques (treatment and
control or two treatment groups). The Cox proportional
hazards model was used to estimate the relative hazard ratio
(HR), for a discrete-time survival analysis of the treatment
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the time variable. Though the sample sizes were small, model
diagnostics supported the use of the Cox proportional
hazards model. All statistical analyses for calculation of the
efﬁcacy of the different interventions were performed using
SAS software (version 9.1; SAS Institute) and StatXact
software (version 6.3; Cytel). For infected macaques, a linear
mixed effects model was ﬁt to the log10 of viral load with the
macaques as a random effect and group (treatment or
control) and time (weeks after peak viral load) as ﬁxed effects.
Results
PrEP Efficacy of Daily FTC and FTC/TDF Combinations
Figure 2 shows the rate of infection in animals that
received PrEP and in 18 untreated control macaques based
on the ﬁrst detectable viral RNA in plasma. Untreated
macaques were infected after a median of two rectal
exposures (mean, four rectal exposures). This suggests that
an animal receiving PrEP and remaining uninfected after 14
virus challenges would have been protected against a median
of seven transmission events. The majority of control animals
(13/18 or 72%) were infected during the ﬁrst four challenges;
four (22%) were infected between exposures 8 and 12, and
only one macaque (6%) remained uninfected after 14
exposures. Proviral DNA was usually detected at the time of
plasma RNA detection or within 1–2 wk thereafter. Virus-
speciﬁc antibody responses were observed within 7 to 35 d
(median, 21 d) after the ﬁrst detectable RNA in plasma. Three
control macaques had persistently high viral loads in plasma
but remained seronegative. Animals in the PrEP arms were
considered protected from systemic SHIV infection if they
were seronegative and negative for SHIV plasma RNA and
SHIV DNA in PBMCs during PrEP and the following 70 d of
washout in the absence of any drug treatment [31].
All PrEP regimens offered some degree of protection. Of
the six macaques in group 1 receiving FTC only, two were
protected after 14 exposures, whereas four had detectable
viral RNA at exposures 5 (AG-80), 10 (AG-46), 12 (AH-04), and
13 (AG-07); infection in these four macaques was delayed
compared to untreated controls (p ¼ 0.004, exact log-rank
test). These data demonstrate the prophylactic activity of
FTC. Infection was also conﬁrmed by DNA-PCR for provirus
in PBMC and seroconversion observed 3, 1, 2, and 6 wk after
the ﬁrst detectable RNA, respectively. To compare the
temporal probability of risk for SHIV infection in controls
relative to treated animals, Cox proportional HRs were
calculated. Compared to controls, animals receiving FTC had
a 3.8-fold lower risk of infection (Cox HR, 3.8, p ¼ 0.02).
More protection was seen in group 2 (oral FTC and TDF);
four of the six macaques were protected and only two (AG-81
and AI-54) were infected, at exposures 9 and 12. Both
infections were signiﬁcantly delayed from controls (p ¼
0.0004, exact log-rank test). These two macaques were
seropositive 2 wk after the ﬁrst detectable viral RNA in
plasma and both were proviral DNA positive at weeks 10 and
12, respectively. Risk of infection in group 2 macaques
receiving FTC and TDF was signiﬁcantly reduced by 7.8-fold
compared to controls (Cox HR, 7.8, p ¼ 0.008).
Breakthrough Infections Have Blunted Wild-Type Viremias
When PrEP fails to completely prevent transmission, the
antiretroviral regimen may select for viruses with resistance
to the drugs [32]. We therefore continued drug treatment in
the six animals that failed PrEP in groups 1 and 2 and
followed virus load dynamics and drug resistance emergence.
Differences were ﬁrst noted in acute viremia between
breakthrough and control infections. Figure 3 compares
virus loads in the breakthrough infections and 10 untreated
macaques with sufﬁcient longitudinal data. The mean peak
viremia in the six treated macaques was 4.9 6 0.5 log10 RNA
copies/ml, 2.0 log10 lower than in untreated controls (6.9 6
0.3 log10 RNA; p ¼ 0.007, Mann-Whitney test; Figure 3). This
difference was maintained up to week 11 as virus loads
declined at similar rates in both groups ( 0.24 6 0.02 log10/wk
and  0.24 6 0.03 log10/wk respectively; p ¼ 0.99). Figure 4
shows that three FTC and one FTC/TDF failures had the ﬁrst
undetectable virus loads as early as weeks 3 (AG-07), 4 (AH-
04), 7 (AG-81), and 11 (AG-80) after the peak viremia. All four
animals maintained low or undetectable virus loads for up to
20 wk. In contrast, all 10 untreated macaques had detectable
virus loads during a median follow-up period of 7 wk (range,
5–40 wk; Figure 3).
Sequence analysis of SIV RT showed that all six break-
through infections were initiated with wild-type virus. Four
animals had no evidence of drug resistance by both sensitive
and conventional testing despite extended (median, 23 wk;
range, 13–29 wk) treatment. Two animals had M184V (AG-46;
Figure 2. Protection against Repeated Rectal Virus Exposures by Daily or Intermittent PrEP
Each survival curve represents the cumulative proportion of uninfected macaques as a function of the number of weekly rectal exposures. Protected
animals in groups 1–4 remained negative after a mean washout out of 27 wk (range, 17–60 wk).
doi:10.1371/journal.pmed.0050028.g002
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associated with FTC resistance 10 and 3 wk after the ﬁrst
detectable RNA, respectively (Figure 4). The tenofovir-
associated K65R mutation was not detected in the two
animals receiving FTC/TDF.
Full Protection by Daily or Intermittent PrEP
In an effort to completely block SHIV transmission, we
administered subcutaneously FTC (20 mg/kg) and a higher
dose of tenofovir (22 mg/kg) to a third group of six macaques
(group 3). All of the six macaques that received this daily PrEP
regimen remained uninfected after 14 exposures (p¼0.00005
compared to untreated controls, exact log-rank test; Figure
2). We also assessed if PrEP given intermittently around each
virus exposure is equally protective to daily PrEP. A group of
six macaques was injected subcutaneously with this highly
effective regimen only 2 h before and 24 h after each weekly
Figure 3. Breakthrough Infections during PrEP Show Blunted Acute Viremias
Each time point represents the mean virus load observed in treated (n¼6) or untreated control (n¼10) macaques. Time 0 indicates the peak plasma
virus load. Bars denote the standard error of the mean.
doi:10.1371/journal.pmed.0050028.g003
Figure 4. Dynamics of Infection in Animals Infected during PrEP with FTC (AG-80, AG-46, AH-04, and AG-07) or FTC/TDF (AG-81 and AI-54)
Red circles indicate detectable M184V/I mutation; wild-type sequences are shown in blue. Open circles indicate time points that were not genotyped.
The first detectable antibody response is shown as red arrows. The broken line denotes the limit of detection of the virus load assay (50 copies/ml).
doi:10.1371/journal.pmed.0050028.g004
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and all were found to be protected from infection (Figure 2).
None of the animals were seropositive or had detectable viral
sequences either in plasma or PBMCs at any of the weekly
time points during the 14-wk intermittent PrEP period and
up to 70 d thereafter.
Discussion
In this study, we investigated the relationship between PrEP
antiviral activity and protection by using a repeat-exposure
macaque model that closely resembles human transmission.
At dosing equivalent to that used in humans, we found that
daily FTC was partially protective, and that the addition of
TDF increased effectiveness. We also show that subcutaneous
FTC and high-dose tenofovir completely blocked rectal
transmission. These ﬁndings show that full protection against
repeated exposures by daily PrEP is possible in a primate
model, and that PrEP effectiveness correlates with increases
in antiviral activity.
None of the protected animals showed any evidence of
transient systemic infection, likely reﬂecting the ability of
FTC and tenofovir to effectively block the earliest SHIV
infections, possibly at the mucosal point of entry, before
signiﬁcant systemic dissemination of the virus occurs. Since
inhibiting virus establishment shortly after exposure may be
critical to PrEP efﬁcacy, we also explored if PrEP given
intermittently around each virus exposure could be equally
protective to daily PrEP. Earlier studies in newborn macaques
exposed orally to a highly virulent SIVmac251 strain have
shown the promise of short PrEP interventions [33,34].
Intermittent PrEP modalities are highly desirable because of
their convenience, potential cost-effectiveness, and lower
risks of drug toxicity. Both FTC and tenofovir have long (40
to .60 h) intracellular half-lives in humans [16–18] suggesting
the possibility of extended prophylactic activity when
administered around virus exposures. We found FTC/teno-
fovir given intermittently as a two-dose PrEP around each of
14 weekly virus exposures to be as fully protective as the same
regimen given daily. Therefore, intermittent PrEP with
potent regimens are highly promising modalities. Evaluation
of intermittent PrEP with different drug combinations,
possibly of different classes, and deﬁning minimal dose
requirement and optimal timing relative to virus exposure
will all be important.
While many biologic similarities exist between rectal and
vaginal HIV transmission, some differences in the early
events of mucosal infection and dissemination kinetics are
possible [8,35]. Therefore, it is important to conﬁrm the PrEP
efﬁcacy of these regimens against vaginal transmission in
appropriate macaque models. Although daily PrEP with a
Truvada-equivalent dosing was highly effective, a regimen
with more tenofovir was required to completely block
transmission in this model. However, the dose of tenofovir
in this regimen would likely be toxic in humans. More work in
macaque models could possibly identify two- or three-drug
combinations that are fully protective and yet carry low risks
of toxicity. The increasing availability of new drugs in
different classes such as those that block viral integration or
entry through CCR5 will provide additional possibilities. The
results of such animal studies may help guide designs of
clinical trials that will ultimately measure effectiveness of
various PrEP regimens against sexual HIV transmission.
Initial macaque studies with tenofovir used single and non-
physiologic doses of SHIV or SIV (10
3 to 10
5 TCID50) capable
of yielding high infection rates in untreated controls
[10,11,33,34]. We used a more physiological virus dose that
fell within the upper range of viral load observed in human
semen during acute HIV-1 infection [20]. The repeated
nature of the model has also the advantage of evaluating
protection over multiple transmission events. The infection
of control macaques after a median of two exposures suggests
that treated animals that remain uninfected after 14
challenges were protected over a median of seven trans-
mission events. This model maintains high stringency,
increases statistical power, provides improved estimations
of risk reductions, and reduces the number of macaques [36].
Although a repeat-challenge model is more relevant to
human transmission, which typically requires multiple ex-
posures, a disadvantage of the model is that it is logistically
demanding over a long period of time. This limits the ability
to do multiple concurrent arms, which raises a potential for
bias. However, animal studies with non-concurrent arms can
be well controlled. In our study, we have staggered inter-
ventions because of logistic feasibility and to prevent
unnecessary use of animals. All animal procedures were done
under identical conditions by the same personnel and
experimental protocol, thus minimizing the potential for
bias. Likewise, it is not known if repeated exposures to the
virus can ultimately alter susceptibility to infection. The
similar infection rates observed among previously or newly
exposed animals suggest that the impact of repeated
exposures on susceptibility to infection is minimal [12,37].
Several important observations were made from the
longitudinal analysis of the breakthrough infections. The
ﬁnding that wild-type SHIV initiated all six infections
suggests that PrEP failure in these animals is due to residual
virus replication in cells not protected by drugs, rather than a
rapid selection of a drug-resistant virus. Of the four animals
infected during FTC treatment, only one selected resistant
viruses, while an FTC-resistant virus emerged in one of two
animals that failed FTC/TDF PrEP. The absence of tenofovir
resistance in both macaques is consistent with clinical
observations showing resistance to FTC and not tenofovir
as the most frequent pathway of resistance to Truvada [38].
The two macaques in which FTC-resistant mutants emerged
had the highest peak viremias, suggesting that selection of
drug resistance may be facilitated by higher virus replication.
Thus, lower acute viremias may have diminished the risk of
resistance during extended treatment with FTC or FTC/TDF.
Similar blunted viremias during early infection have been
noted in macaques failing PrEP with an orally administered
CCR5 inhibitor [39]. These data underscore the potential
differences in virus load and drug resistance dynamics during
PrEP failures from those in mono- or dual drug therapy of
established infections [21,22,40,41].
The attenuated acute viremias may have additional clinical
and public health implications. It is well established that
massive depletion of CD4
þ T cells, speciﬁcally CD4
þ memory
T cells, begins in the acute stage of SIV as well as HIV-1
infection in the gut and other lymphoid tissues, and is
generally proportional to the degree of virus replication [42–
44]. Substantial reductions in acute viremia may conceivably
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þ T cell depletion, help preserve immune
function, and attenuate the course of HIV infection. In
humans, reduction in virus set points by 1 log10 have been
estimated to double the time to progression to HIV disease
[45]. Reductions in virus loads in the animals that failed PrEP
were apparent at the ﬁrst time points before seroconversion
and were sustained under continued drug treatment after all
the animals seroconverted. Blunted viremia during acute
infection in persons who fail PrEP will likely depend on the
period of drug exposure and the potency of the PrEP
regimen. PrEP-treated populations will likely be monitored
by serologic testing for infection to minimize drug exposure
and reduce the risks of drug resistance. The period of drug
exposure will thus depend on the frequency of serologic
testing but will inevitably be at least several weeks long,
enough to affect early CD4
þ T cell depletion. Individuals with
acute infections who have very high virus loads may also play
a key role in the epidemic spread of HIV-1 because they are
more infectious than individuals with chronic infections who
have lower virus loads [46–48]. Therefore, reductions in acute
viremia during PrEP treatment may contribute to decreases
in HIV-1 transmissibility at the population level and could
add to the overall effectiveness of PrEP.
The data from this study demonstrate the potential high
effectiveness of daily or intermittent PrEP against sexual HIV
transmission, support expanding PrEP trials in humans and
identify promising PrEP modalities.
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Editors’ Summary
Background. Each year, some 2.5 million people become newly infected
with HIV, the virus that causes AIDS. A vaccine that protects people
against HIV infection is not likely to become available for at least several
years. Condoms can prevent infection, but they are not 100% effective,
and people do not always use them. Until a vaccine becomes available,
other methods of preventing HIV could save many thousands of lives.
One possibility for preventing HIV is pre-exposure prophylaxis (PrEP). In
this approach, people who are likely to be exposed to the virus could
take medicine to prevent them from becoming infected, in the same way
that medication to protect against malaria is often taken by people
traveling to high-risk areas.
Why Was This Study Done? PrEP has never been shown to be effective
against sexual transmission of HIV in humans. Studies of PrEP in people
at risk for HIV are currently in progress or being planned, but it is not
clear which medications or dosing schedules should be used. The
researchers in this study wanted to explore several possible ways of
giving PrEP in monkeys in order to learn more about how to design
strategies for testing PrEP in humans.
What Did the Researchers Do and Find? The researchers simulated
human exposure to HIV by exposing rhesus macaques (a type of monkey)
to SHIV, a monkey virus (SIV) that has been modified to contain the same
outer protein as HIV. They exposed the macaques to repeated low doses
of SHIV given rectally once per week, to simulate a common route of HIV
transmission in humans. They used five groups of macaques that were all
given the same viral exposure, but received different PrEP regimens: one
group of six animals received only the anti-HIV drug emtricitabine (FTC),
by injection under the skin every day; another six received FTC in
combination with an oral form of the anti-HIV drug tenofovir every day,
both by mouth; six received by injection FTC in combination with a
higher tenofovir dose every day, and six also received by injection FTC in
combination with the high-dose tenofovir, but the treatment was given
only before and after the weekly viral exposure instead of every day. For
comparison, the fifth group of nine macaques (plus another nine from a
previous study) received no anti-HIV medications.
The researchers found that the macaques in any of the four treatment
groups were less likely to become infected than those in the comparison
group. In particular, all of the macaques receiving both FTC and high-
dose tenofovir, whether daily or only around the time of exposure, were
protected from infection. Macaques that did become infected in the
other treatment groups had lower levels of virus in their blood than
those that became infected in the comparison group, but some that
became infected in the treatment groups went on to develop virus that
was resistant to FTC.
What Do These Findings Mean? These results show that PrEP can be
effective in this animal model, and that higher doses and combination
treatments may be more effective than single drugs or lower doses. The
results also suggest that PrEP might work if taken only around the time
of exposure and therefore might not need to be taken every day in
order to be effective. Further, by reducing the levels of HIV in people
who do become infected, PrEP might reduce the chance that these
people will transmit HIV to others before realizing that they themselves
are infected. However, this study also demonstrates that partially
effective PrEP can result in infection with drug-resistant virus, which
might make treatment difficult. Also, the doses of tenofovir used to
achieve maximum protection in these macaques may be higher than
would be safe in humans. Carefully designed human studies will be
needed to determine which, if any, PrEP strategies will be effective in
practice.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/doi:10.1371/journal.pmed.
0050028.
  The US Centers for Disease Control and Prevention (CDC) is
conducting several trials of PrEP
  The AIDS Vaccine Advocacy Coalition and the UCLA Program in Global
Health provide information at PreP Watch
  The UCSF Center for HIV Information’s HIV InSite includes resources on
HIV prevention and treatment
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